Skip Navigation
Menu
Letters |15 March 1997

Treatment of Behcet Disease with Pentoxifylline

Jedd D. Wolchok, MD, PhD

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • Memorial Sloan-Kettering Cancer Center, New York, NY 10021
×
FULL TEXT
TO THE EDITOR:
Yasui and colleagues [1] recently published an interesting report on the efficacy of pentoxifylline in the treatment of three patients with Behcet disease. The precise cause of Behcet disease remains unknown; however, international diagnostic criteria include the classic symptoms of oral and genital ulcerations, uveitis, and skin lesions [2].
I was intrigued by one possible mechanism of action of pentoxifylline that may help elucidate the cause of Behcet disease. This compound, a methylxanthine derivative, has been shown to inhibit the production of various proinflammatory cytokines, especially tumor necrosis factor-α (TNF-α) [3]. Interestingly, levels of TNF-α induced by lipopolysaccharide have been shown to be increased in peripheral blood mononuclear cells from patients with Behcet disease when compared with levels in age-matched healthy controls [4]. Thus, TNF-α may play a substantial role in the pathogenesis of Behcet disease, either directly or through the induction of other cytokines. This proposed mechanism is supported by the finding that thalidomide, an inhibitor of TNF-α action, also reduces mucosal ulcerations in patients with Behcet disease [2].
FULL TEXT
PDF
Not Available
Citations
Citation

Wolchok JD. Treatment of Behcet Disease with Pentoxifylline. Ann Intern Med. 1997;126:493. doi: 10.7326/0003-4819-126-6-199703150-00020

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 1997;126(6):493.

DOI: 10.7326/0003-4819-126-6-199703150-00020

2 Citations
CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×